A study of the association between the sFlt-1/PIGF ratio and preeclampsia in Xinjiang Uygur Autonomous Region of China

References

• Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. Cardiovasc Res. 2014;101:579–586.
   PubMed Web of Science ®Google Scholar
• Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31:141–146.
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799.
   PubMed Web of Science ®Google Scholar
• Hod T, Cerdeira AS, Karumanchi SA. Molecular mechanisms of preeclampsia. Cold Spring Harb Perspect Med. 2015;5:a023473.
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–1074.
   PubMed Web of Science ®Google Scholar
• Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy. 2011;2011:481095.
   PubMedGoogle Scholar
• Grill S, Rusterholz C, Zanetti-Dallenbach R, et al. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol. 2009;7:70.
   PubMed Web of Science ®Google Scholar
• Wu P, van den Berg C, Alfirevic Z, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. IJMS. 2015;16:23035–23056.
   Google Scholar
• Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem. 2010;43:768–770.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Staff AC, Braekke K, Harsem NK, et al. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstetr Gynecol Reprod Biol. 2005;122:33–39.
   PubMed Web of Science ®Google Scholar
• Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50:1702–1703.
   PubMed Web of Science ®Google Scholar
• Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstetr Gynecol. 2007;109:1368–1374.
   PubMed Web of Science ®Google Scholar
• Kita N, Mitsushita J. A possible placental factor for preeclampsia: sFlt-1. Curr Med Chem. 2008;15:711–715.
   PubMed Web of Science ®Google Scholar
• Tarasevičienė V, Grybauskienė R, Mačiulevičienė R. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics. Medicina. 2016;52:349–353.
   PubMedGoogle Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Yearbook of pathology & laboratory. Nat Med. 2006;12:642.
   PubMed Web of Science ®Google Scholar
• Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22.
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911–919.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstetr Gynecol. 2012;206:58.e1–58.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–352.
   PubMed Web of Science ®Google Scholar
• De OL, Peraçoli JC, Peraçoli MT, et al. sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia. Pregnancy Hypertension. 2013;3:191–195.
   PubMed Web of Science ®Google Scholar
• Gilstrap L, Ramin S. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia; 2002;77:67–75.
   Google Scholar
• Simhan H, Caritis S. Prevention of preterm delivery. N Engl J Med. 2007;357:477–1980.
   PubMed Web of Science ®Google Scholar
• Saleh L, Verdonk K, Jan Danser AH, et al. The sFlt-1/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort. Eur J Obstetr Gynecol Reprod Biol. 2016;199:121–126.
   PubMed Web of Science ®Google Scholar
• Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstetr Gynecol. 2001;97:261–267.
   PubMed Web of Science ®Google Scholar
• Makowsky K, Schücking BA. Management of women with obesity in pregnancy. Praev Gesundheitsf. 2012;7:87–94.
   Google Scholar
• Perales A, Delgado JL, De La Calle M, et al. sFlt-1/PlGF for early-onset pre-eclampsia prediction: STEPS (study of early pre-eclampsia in Spain). Ultrasound Obstetr Gynecol. 2016;50:373–382.
   Google Scholar
• Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357:53–56.
   PubMed Web of Science ®Google Scholar
• Pegoraro RJ, Ranjith N. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction. Cardiovasc J S Afr. 2005;16:266–270.
   PubMedGoogle Scholar
• El Sahly HM, Reich RA, Dou SJ, et al. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Infect Dis. 2004;36:106–108.
   Web of Science ®Google Scholar